{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:03:38Z","timestamp":1784192618134,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16146-4","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T05:26:03Z","timestamp":1779513963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative fall risk of patients treated with novel androgen receptor antagonists in prostate cancer: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Chunhua","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuesu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuangcheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiacheng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyang","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Langping","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"issue":"3","key":"16146_CR1","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/endrev\/bnab002","volume":"42","author":"K Desai","year":"2021","unstructured":"Desai K, McManus JM, Sharifi N. Hormonal therapy for prostate cancer. Endocr Rev. 2021;42(3):354\u201373. https:\/\/doi.org\/10.1210\/endrev\/bnab002.","journal-title":"Endocr Rev"},{"key":"16146_CR2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","volume":"70","author":"MY Teo","year":"2019","unstructured":"Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med. 2019;70:479\u201399. https:\/\/doi.org\/10.1146\/annurev-med-051517-011947.","journal-title":"Annu Rev Med"},{"key":"16146_CR3","unstructured":"National Comprehensive Cancer Network. Prostate cancer. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/. Accessed 17 Apr 2024."},{"issue":"2","key":"16146_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 update: treatment of relapsing and metastatic Prostate Cancer. Eur Urol. 2024;86(2):164\u201382. https:\/\/doi.org\/10.1016\/j.eururo.2024.04.010.","journal-title":"Eur Urol"},{"issue":"9","key":"16146_CR5","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","volume":"31","author":"C Parker","year":"2020","unstructured":"Parker C, Castro E, Fizazi K, et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(9):1119\u201334. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.011.","journal-title":"Ann Oncol"},{"issue":"15","key":"16146_CR6","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1093\/ajhp\/zxac105","volume":"79","author":"C Chung","year":"2022","unstructured":"Chung C, Abboud K. Targeting the androgen receptor signaling pathway in advanced prostate cancer. Am J Health Syst Pharm. 2022;79(15):1224\u201335. https:\/\/doi.org\/10.1093\/ajhp\/zxac105.","journal-title":"Am J Health Syst Pharm"},{"issue":"6","key":"16146_CR7","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1097\/MOU.0000000000001341","volume":"35","author":"R Iaxx","year":"2025","unstructured":"Iaxx R, Teyssonneau D, Fallaha C, Grouthier V, Roubaud G. Toxicities of novel androgen receptor pathway inhibitor targeted therapies in advanced prostate cancer. Curr Opin Urol. 2025;35(6):696\u2013706. https:\/\/doi.org\/10.1097\/MOU.0000000000001341.","journal-title":"Curr Opin Urol"},{"issue":"11","key":"16146_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103736","volume":"9","author":"H Bolek","year":"2024","unstructured":"Bolek H, Yazgan SC, Yeked\u00fcz E, et al. Androgen receptor pathway inhibitors and drug-drug interactions in prostate cancer. ESMO Open. 2024;9(11):103736. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103736.","journal-title":"ESMO Open"},{"issue":"4","key":"16146_CR9","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s00520-020-05830-1","volume":"29","author":"B Bressi","year":"2021","unstructured":"Bressi B, Cagliari M, Contesini M, et al. Physical exercise for bone health in men with prostate cancer receiving androgen deprivation therapy: a systematic review. Support Care Cancer. 2021;29(4):1811\u201324. https:\/\/doi.org\/10.1007\/s00520-020-05830-1.","journal-title":"Support Care Cancer"},{"issue":"15","key":"16146_CR10","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1136\/bjsports-2019-101512","volume":"54","author":"C Sherrington","year":"2020","unstructured":"Sherrington C, Fairhall N, Wallbank G, et al. Exercise for preventing falls in older people living in the community: an abridged Cochrane systematic review. Br J Sports Med. 2020;54(15):885\u201391. https:\/\/doi.org\/10.1136\/bjsports-2019-101512.","journal-title":"Br J Sports Med"},{"issue":"3","key":"16146_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013258.pub2","volume":"3","author":"L Clemson","year":"2023","unstructured":"Clemson L, Stark S, Pighills AC, et al. Environmental interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2023;3(3):CD013258. https:\/\/doi.org\/10.1002\/14651858.CD013258.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"16146_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05687-7","volume":"22","author":"KM Winters-Stone","year":"2021","unstructured":"Winters-Stone KM, Li F, Horak F, et al. Protocol for GET FIT Prostate: a randomized, controlled trial of group exercise training for fall prevention and functional improvements during and after treatment for prostate cancer. Trials. 2021;22(1):775. https:\/\/doi.org\/10.1186\/s13063-021-05687-7.","journal-title":"Trials"},{"issue":"11","key":"16146_CR13","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1093\/jnci\/djae155","volume":"116","author":"KS Faraj","year":"2024","unstructured":"Faraj KS, Oerline M, Kaufman SR, et al. Adverse events in men with advanced prostate cancer treated with androgen biosynthesis inhibitors and androgen receptor inhibitors. J Natl Cancer Inst. 2024;116(11):1817\u201324. https:\/\/doi.org\/10.1093\/jnci\/djae155.","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"16146_CR14","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrclinonc.2014.127","volume":"11","author":"JE Bower","year":"2014","unstructured":"Bower JE. Cancer-related fatigue--mechanisms, risk factors, and treatments. Nat Rev Clin Oncol. 2014;11(10):597\u2013609. https:\/\/doi.org\/10.1038\/nrclinonc.2014.127.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"16146_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01042-7","volume":"7","author":"Y He","year":"2022","unstructured":"He Y, Xu W, Xiao YT, Huang H, Gu D, Ren S. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal Transduct Target Ther. 2022;7(1):198. https:\/\/doi.org\/10.1038\/s41392-022-01042-7.","journal-title":"Signal Transduct Target Ther"},{"issue":"16","key":"16146_CR16","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jama.2025.0228","volume":"333","author":"R Raychaudhuri","year":"2025","unstructured":"Raychaudhuri R, Lin DW, Montgomery RB. Prostate cancer: a review. JAMA. 2025;333(16):1433\u201346. https:\/\/doi.org\/10.1001\/jama.2025.0228.","journal-title":"JAMA"},{"key":"16146_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906. https:\/\/doi.org\/10.1016\/j.ijsu.2021.105906.","journal-title":"Int J Surg"},{"key":"16146_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008. https:\/\/doi.org\/10.1136\/bmj.j4008.","journal-title":"BMJ"},{"key":"16146_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"issue":"4","key":"16146_CR20","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","volume":"24","author":"CJ Sweeney","year":"2023","unstructured":"Sweeney CJ, Martin AJ, Stockler MR, et al. Testosterone suppression plus Enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(4):323\u201334. https:\/\/doi.org\/10.1016\/S1470-2045(23)00063-3.","journal-title":"Lancet Oncol"},{"issue":"15","key":"16146_CR21","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1200\/JCO.22.00193","volume":"40","author":"AJ Armstrong","year":"2022","unstructured":"Armstrong AJ, Azad AA, Iguchi T, et al. Improved survival with Enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2022;40(15):1616\u201322. https:\/\/doi.org\/10.1200\/JCO.22.00193.","journal-title":"J Clin Oncol"},{"issue":"1","key":"16146_CR22","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.eururo.2020.08.011","volume":"79","author":"MR Smith","year":"2021","unstructured":"Smith MR, Saad F, Chowdhury S, et al. Apalutamide and overall survival in prostate cancer. Eur Urol. 2021;79(1):150\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2020.08.011.","journal-title":"Eur Urol"},{"issue":"23","key":"16146_CR23","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","volume":"382","author":"CN Sternberg","year":"2020","unstructured":"Sternberg CN, Fizazi K, Saad F, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2020;382(23):2197\u2013206. https:\/\/doi.org\/10.1056\/NEJMoa2003892.","journal-title":"N Engl J Med"},{"issue":"11","key":"16146_CR24","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","volume":"383","author":"K Fizazi","year":"2020","unstructured":"Fizazi K, Shore N, Tammela TL, et al. Nonmetastatic, castration-resistant prostate cancer and survival with Darolutamide. N Engl J Med. 2020;383(11):1040\u20139. https:\/\/doi.org\/10.1056\/NEJMoa2001342.","journal-title":"N Engl J Med"},{"issue":"3","key":"16146_CR25","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.eururo.2020.04.061","volume":"78","author":"AJ Armstrong","year":"2020","unstructured":"Armstrong AJ, Lin P, Tombal B, et al. Five-year survival prediction and safety outcomes with Enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer from the PREVAIL Trial. Eur Urol. 2020;78(3):347\u201357. https:\/\/doi.org\/10.1016\/j.eururo.2020.04.061.","journal-title":"Eur Urol"},{"issue":"18","key":"16146_CR26","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1200\/JCO.2015.64.9285","volume":"34","author":"DF Penson","year":"2016","unstructured":"Penson DF, Armstrong AJ, Concepcion R, et al. Enzalutamide versus Bicalutamide in castration-resistant prostate cancer: the STRIVE Trial. J Clin Oncol. 2016;34(18):2098\u2013106. https:\/\/doi.org\/10.1200\/JCO.2015.64.9285.","journal-title":"J Clin Oncol"},{"issue":"36","key":"16146_CR27","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1200\/JCO-24-01798","volume":"42","author":"F Saad","year":"2024","unstructured":"Saad F, Vjaters E, Shore N, et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the Phase III ARANOTE Trial. J Clin Oncol. 2024;42(36):4271\u201381. https:\/\/doi.org\/10.1200\/JCO-24-01798.","journal-title":"J Clin Oncol"},{"issue":"16","key":"16146_CR28","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland SJ, de Almeida Luz M, De Giorgi U, et al. Improved outcomes with Enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2023;389(16):1453\u201365. https:\/\/doi.org\/10.1056\/NEJMoa2303974.","journal-title":"N Engl J Med"},{"issue":"20","key":"16146_CR29","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi KN, Chowdhury S, Bjartell A, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, Phase III TITAN Study. J Clin Oncol. 2021;39(20):2294\u2013303. https:\/\/doi.org\/10.1200\/JCO.20.03488.","journal-title":"J Clin Oncol"},{"issue":"12","key":"16146_CR30","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386(12):1132\u201342. https:\/\/doi.org\/10.1056\/NEJMoa2119115.","journal-title":"N Engl J Med"},{"issue":"2","key":"16146_CR31","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jgo.2019.06.006","volume":"11","author":"KR Covington","year":"2020","unstructured":"Covington KR, Atler KE, Schmid AA, Pergolotti M. Understanding fall risk for older adults with cancer: an evaluation of experts\u2019 perceptions. J Geriatr Oncol. 2020;11(2):263\u20139. https:\/\/doi.org\/10.1016\/j.jgo.2019.06.006.","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"16146_CR32","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.cger.2018.08.010","volume":"35","author":"DJ Bolding","year":"2019","unstructured":"Bolding DJ, Corman E. Falls in the geriatric patient. Clin Geriatr Med. 2019;35(1):115\u201326. https:\/\/doi.org\/10.1016\/j.cger.2018.08.010.","journal-title":"Clin Geriatr Med"},{"issue":"7","key":"16146_CR33","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1001\/jamaoncol.2024.1549","volume":"10","author":"O El-Taji","year":"2024","unstructured":"El-Taji O, Taktak S, Jones C, Brown M, Clarke N, Sachdeva A. Cardiovascular events and androgen receptor signaling inhibitors in advanced prostate cancer: a systematic review and meta-analysis. JAMA Oncol. 2024;10(7):874\u201384. https:\/\/doi.org\/10.1001\/jamaoncol.2024.1549.","journal-title":"JAMA Oncol"},{"issue":"5","key":"16146_CR34","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.clgc.2018.07.017","volume":"16","author":"K Fizazi","year":"2018","unstructured":"Fizazi K, Smith MR, Tombal B. Clinical development of Darolutamide: a novel androgen receptor antagonist for the treatment of prostate cancer. Clin Genitourin Cancer. 2018;16(5):332\u201340. https:\/\/doi.org\/10.1016\/j.clgc.2018.07.017.","journal-title":"Clin Genitourin Cancer"},{"issue":"9","key":"16146_CR35","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.clon.2020.03.011","volume":"32","author":"R Morris","year":"2020","unstructured":"Morris R, Lewis A. Falls and cancer. Clin Oncol. 2020;32(9):569\u201378. https:\/\/doi.org\/10.1016\/j.clon.2020.03.011.","journal-title":"Clin Oncol"},{"issue":"4","key":"16146_CR36","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1188\/20.ONF.457-468","volume":"47","author":"KR Twibell","year":"2020","unstructured":"Twibell KR, Siela D, Delaney L, Avila P, Spradlin AM, Coers G. Perspectives of inpatients with cancer on engagement in fall prevention. Oncol Nurs Forum. 2020;47(4):457\u201368. https:\/\/doi.org\/10.1188\/20.ONF.457-468.","journal-title":"Oncol Nurs Forum"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16146-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16146-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16146-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:09:39Z","timestamp":1784189379000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16146-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16146"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16146-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"19 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"849"}}